The effect of a phytoestrogen intervention and impact of genetic factors on tumor proliferation markers among Swedish patients with prostate cancer: study protocol for the randomized controlled PRODICA trial

Abstract

Abstract Background A high intake of phytoestrogens, found in soy, rye, and seeds, is associated with a reduced risk of a prostate cancer diagnosis. Previously, we found that the overall decreased risk of prostate cancer diagnosis in males with a high intake of phytoestrogens was strongly modified by a nucleotide sequence variant in the estrogen receptor-beta (ERβ) gene. However, we do not know if phytoestrogens can inhibit the growth of prostate cancer in males with established diseases. If there is an inhibition or a delay, there is reason to believe that different variants of the ERβ gene will modify the effect. Therefore, we designed an intervention study to investigate the effect of the addition of foods high in phytoestrogens and their interaction with ERβ genotype on prostate tumor proliferation in patients with prostate cancer. Method The PRODICA-trial is a randomized ongoing intervention study in patients with low- and intermediate-risk prostate cancer with Gleason score < 8, prostate-specific antigen (PSA) < 20, and scheduled for radical prostatectomy. The study is conducted at Sahlgrenska University Hospital in Gothenburg, Sweden. The intervention consists of a daily intake of soybeans and flaxseeds (~ 200 mg of phytoestrogens) until the surgery, approximately 6 w. The aim is to recruit 200 participants. The primary outcome is the difference in the proliferation marker Ki-67 between the intervention- and the control groups. The genotype of ERβ will be investigated as an effect-modifying factor. Secondary outcomes include e.g. concentrations of PSA and steroid hormones in blood. Discussion The results of the PRODICA-trial will contribute important information on the relevance of increasing the intake of phytoestrogens in patients with prostate cancer who want to make dietary changes to improve the prognosis of their cancer. If genetic factors turn out to influence the effect of the intervention diet, dietary advice can be given to patients who most likely benefit from it. Dietary interventions are cost-effective, non-invasive, and result in few mild side effects. Lastly, the project will provide basic pathophysiological insights which could be relevant in the development of treatment strategies for patients with prostate cancer. Trial registration: ClinicalTrials.gov, NCT02759380, Registered on 3 May 2016.